IDT Australia Limited (ASX:IDT)

Market Cap	47.26M
Revenue (ttm)	18.77M
Net Income (ttm)	-4.80M
Shares Out	429.68M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	294,897
Average Volume	646,183
Open	0.1050
Previous Close	0.1000
Day's Range	0.1050 - 0.1100
52-Week Range	0.0800 - 0.1450
Beta	1.25
RSI	57.81
Earnings Date	May 20, 2025

About IDT Australia

IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the Unites States. and internationally. It offers microbiological and analytical testing, clinical packaging, and pharmacy services. The company also provides medicinal cannabis and psychedelics; oral finished doses; and aseptic fill and finish solutions for liquid and lyophilised forms. In addition, it offers mRNA and ADCs. Further, the company provid...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1975
• Employees: 100
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IDT

Financial Performance

In 2024, IDT Australia's revenue was 14.02 million, an increase of 100.67% compared to the previous year's 6.99 million. Losses were -5.41 million, -36.30% less than in 2023.